[go: up one dir, main page]

MX2017002954A - Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol. - Google Patents

Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol.

Info

Publication number
MX2017002954A
MX2017002954A MX2017002954A MX2017002954A MX2017002954A MX 2017002954 A MX2017002954 A MX 2017002954A MX 2017002954 A MX2017002954 A MX 2017002954A MX 2017002954 A MX2017002954 A MX 2017002954A MX 2017002954 A MX2017002954 A MX 2017002954A
Authority
MX
Mexico
Prior art keywords
solid
forms
diclorophenil
cristial
carboxi
Prior art date
Application number
MX2017002954A
Other languages
English (en)
Other versions
MX374012B (es
Inventor
Paul Girard Kevin
j jensen Andrew
Nicole Jones Kris
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54199901&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017002954(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017002954A publication Critical patent/MX2017002954A/es
Publication of MX374012B publication Critical patent/MX374012B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a formas solidas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol y a métodos para su preparación. La invención también se refiere a composiciones farmacéuticas que contienen al menos una forma sólida y al uso profiláctico o terapéutico de esas composiciones y formas solidas.
MX2017002954A 2014-09-08 2015-08-31 Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol. MX374012B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462047614P 2014-09-08 2014-09-08
US201562203953P 2015-08-12 2015-08-12
PCT/IB2015/056597 WO2016038500A1 (en) 2014-09-08 2015-08-31 Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole

Publications (2)

Publication Number Publication Date
MX2017002954A true MX2017002954A (es) 2017-06-15
MX374012B MX374012B (es) 2020-07-22

Family

ID=54199901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017002954A MX374012B (es) 2014-09-08 2015-08-31 Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.

Country Status (24)

Country Link
US (1) US9770441B1 (es)
EP (3) EP3191461B1 (es)
JP (5) JP2016065042A (es)
KR (1) KR102004059B1 (es)
CN (2) CN106715405A (es)
AU (1) AU2015313875B2 (es)
BR (1) BR112017003421B1 (es)
CA (1) CA2903194A1 (es)
CY (1) CY1124843T1 (es)
DK (1) DK3977993T3 (es)
ES (2) ES2901785T3 (es)
FI (1) FI3977993T3 (es)
HR (1) HRP20211834T1 (es)
HU (2) HUE056583T2 (es)
IL (1) IL251037B1 (es)
LT (1) LT3191461T (es)
MX (1) MX374012B (es)
PL (2) PL3977993T3 (es)
PT (2) PT3191461T (es)
RS (1) RS62634B1 (es)
SG (1) SG11201700958YA (es)
SI (2) SI3977993T1 (es)
TW (1) TWI644902B (es)
WO (1) WO2016038500A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571950A (en) * 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
US12268669B2 (en) 2018-12-20 2025-04-08 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
JP7622338B2 (ja) * 2019-04-11 2025-01-28 インケ、ソシエダ、アノニマ ２－（３，５－ジクロロフェニル）－６－ベンズオキサゾールカルボン酸１－デオキシ－１－メチルアミノ－ｄ－グルシトールの製造方法
HRP20250159T1 (hr) 2019-05-16 2025-03-28 Assia Chemical Industries Ltd. Kruti oblici tafamidisa i njegovih soli
WO2021001858A1 (en) * 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
EP4059926A4 (en) 2019-11-15 2022-12-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF
KR20220114626A (ko) * 2019-12-20 2022-08-17 화이자 아일랜드 파마슈티컬즈 6-카르복시 벤족사졸 유도체의 효율적인 제조 방법
WO2021152623A1 (en) * 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt
WO2021232619A1 (zh) * 2020-05-19 2021-11-25 苏州科睿思制药有限公司 一种他发米帝司游离酸的晶型及其制备方法和用途
US20230265059A1 (en) * 2020-07-04 2023-08-24 Nuray Chemicals Private Limited Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof
WO2022084790A1 (en) * 2020-10-19 2022-04-28 Glenmark Life Sciences Limited Process for preparation of tafamidis and salts thereof
WO2022107166A1 (en) * 2020-11-20 2022-05-27 Natco Pharma Limited Novel crystalline form of tafamidis and its process thereof
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN114907283B (zh) * 2021-02-07 2025-01-28 南京正大天晴制药有限公司 一种2-(3，5-二氯苯基)-苯并噁唑-6-羧酸的制备方法
CN114989106A (zh) * 2021-02-09 2022-09-02 齐鲁制药有限公司 氯苯唑酸的新晶型及其制备方法
EP4083027A1 (en) * 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
WO2023091534A1 (en) 2021-11-17 2023-05-25 Teva Pharmaceuticals International Gmbh Solid state form of tafamidis
CN119604278A (zh) 2022-07-28 2025-03-11 辉瑞大药厂 氯苯唑酸药物组合物
WO2024084362A1 (en) * 2022-10-17 2024-04-25 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of crystalline form of tafamidis
US11980685B1 (en) 2022-12-23 2024-05-14 Tap Pharmaceuticals, Ag Liquid pharmaceutical formulations of tafamidis
US11878081B1 (en) 2022-12-23 2024-01-23 Tap Pharmaceuticals Ag Pharmaceutical formulations of tafamidis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
AU2007330478B2 (en) * 2006-12-06 2011-09-08 Conatus Pharmaceuticals, Inc. Crystalline forms of ( 3 S ) -3- [N- (N' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluorophenoxy) -4-oxopentanoic acid
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
CN103781770B (zh) 2011-09-16 2016-04-13 辉瑞公司 转甲状腺素蛋白解离抑制剂的固体形式
US9499527B2 (en) * 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
HRP20250159T1 (hr) 2019-05-16 2025-03-28 Assia Chemical Industries Ltd. Kruti oblici tafamidisa i njegovih soli
WO2021001858A1 (en) 2019-07-04 2021-01-07 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof
WO2021152623A1 (en) 2020-01-27 2021-08-05 Dr. Reddy’S Laboratories Limited Improved processes for the preparation of tafamidis and its meglumine salt

Also Published As

Publication number Publication date
US9770441B1 (en) 2017-09-26
CA2903194A1 (en) 2016-03-08
BR112017003421B1 (pt) 2023-10-10
EP3191461B1 (en) 2021-11-03
EP4349406A2 (en) 2024-04-10
WO2016038500A1 (en) 2016-03-17
US20170273953A1 (en) 2017-09-28
NZ766084A (en) 2023-12-22
FI3977993T3 (fi) 2024-03-25
CN115368313A (zh) 2022-11-22
PT3977993T (pt) 2024-04-01
ES2975633T3 (es) 2024-07-10
PL3191461T3 (pl) 2022-02-07
MX374012B (es) 2020-07-22
HRP20211834T1 (hr) 2022-03-04
HUE056583T2 (hu) 2022-02-28
CN106715405A (zh) 2017-05-24
JP2023134645A (ja) 2023-09-27
BR112017003421A2 (pt) 2017-11-28
JP7357525B2 (ja) 2023-10-06
SI3977993T1 (sl) 2024-05-31
EP4349406B1 (en) 2025-12-03
HUE065233T2 (hu) 2024-05-28
DK3977993T3 (da) 2024-02-19
EP4349406A3 (en) 2024-05-22
IL251037A0 (en) 2017-04-30
SG11201700958YA (en) 2017-03-30
RS62634B1 (sr) 2021-12-31
KR102004059B1 (ko) 2019-07-25
EP3191461A1 (en) 2017-07-19
TWI644902B (zh) 2018-12-21
KR20170040314A (ko) 2017-04-12
JP2016065042A (ja) 2016-04-28
JP2020055832A (ja) 2020-04-09
LT3191461T (lt) 2021-12-10
RU2017107235A (ru) 2018-10-11
AU2015313875B2 (en) 2018-03-15
AU2015313875A1 (en) 2017-03-02
ES2901785T3 (es) 2022-03-23
JP2025108584A (ja) 2025-07-23
EP3977993A1 (en) 2022-04-06
PT3191461T (pt) 2021-12-27
NZ729011A (en) 2023-10-27
PL3977993T3 (pl) 2024-05-06
SI3191461T1 (sl) 2022-01-31
RU2692252C2 (ru) 2019-06-24
EP3977993B1 (en) 2024-01-31
RU2017107235A3 (es) 2018-10-11
TW201613880A (en) 2016-04-16
CY1124843T1 (el) 2022-11-25
JP2022024014A (ja) 2022-02-08
IL251037B1 (en) 2024-10-01

Similar Documents

Publication Publication Date Title
MX2017002954A (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benz oxazol.
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
BR112016025819A2 (pt) vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico
PT3096785T (pt) Composições imunogénicas que compreendem antigénios de sacáridos capsulares conjugados e utilizações das mesmas
MX2017012009A (es) Derivado de un anillo condensado y metodo de preparacion, compuesto intermedio, composicion farmaceutica y uso del mismo.
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
MX2018002416A (es) Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos.
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
CR20170005A (es) Derivados de insoindolina
CL2013002908A1 (es) Uso de compuestos derivados de bencimidazol-4-carboxamida para el tratamiento profilactico de la neuropatia periferica inducida por quimioterapia .
MX2015012833A (es) Composiciones antibioticas de ceftolozano.
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
CL2017000152A1 (es) Derivados de isoindolinona
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
CL2017000151A1 (es) Derivados de piridona
BR112017007753A2 (pt) uso de uma composição cosmética que compreende ácido 10-hidroxiesteárico.
BR112016028083A2 (pt) Composição oral farmacêutica de isotretinoina e seu processo de preparação
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
MX375918B (es) Composiciones para el tratamiento de la fibrosis y afecciones relacionadas con la fibrosis.

Legal Events

Date Code Title Description
FG Grant or registration